Mar 13, 2021

Novel Alzheimer’s Drug Slows Cognitive Decline in Phase 2 Trial

Posted by in categories: biotech/medical, neuroscience

While topline results from TRAILBLAZER-ALZ showed a 32% slowing of cognitive decline with the anti-amyloid drug donanemab, highly anticipated phase 2 findings provide a more detailed analysis.

Comments are closed.